Silence Therapeutics (SLN) Profit After Tax (2024 - 2026)

Silence Therapeutics has disclosed Profit After Tax across 3 years of filings, most recently posting -$15.0 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$15.0 million, up 47.57% year-over-year; the trailing twelve-month figure through Mar 2026 was -$75.1 million (down 4.97% YoY), and the FY2025 annual result was -$88.6 million, down 95.57% from the prior year.
• Profit After Tax came in at -$15.0 million for Q1 2026 at Silence Therapeutics, down from -$11.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $12.3 million in Q4 2024 to a low of -$35.5 million in Q3 2024.
• The 3-year median for Profit After Tax is -$19.8 million (2024), against an average of -$16.5 million.
• Across the five-year window, Profit After Tax tumbled 1134.0% in 2025 and surged 47.57% in 2026, its largest moves.
• Silence Therapeutics' Profit After Tax stood at $12.3 million in 2024, then sank by 196.02% to -$11.8 million in 2025, then fell by 26.63% to -$15.0 million in 2026.
• The last three Profit After Tax figures came in at -$15.0 million (Q1 2026), -$11.8 million (Q4 2025), and -$21.0 million (Q3 2025), per Business Quant data.